Antihypertensive drug telmisartan inhibits cell proliferation of gastrointestinal stromal tumor cells in vitro

Kobara,Hideki; Fujihara,Shintaro; Iwama,Hisakazu; Matsui,Takanori; Fujimori,Ayako; Chiyo,Taiga; Tingting,Shi; Kobayashi,Nobuya; Nishiyama,Noriko; Yachida,Tatsuo; Tadokoro,Tomoko; Oura,Kyoko; Tani,Joji; Fujita,Koji; Nomura,Takako; Yoneyama,Hirohito; Morishita,Asahiro; Okano,Keiichi; Suzuki,Yasuyuki; Mori,Hirohito; Masaki,Tsutomu

doi:10.3892/mmr.2020.11144

Antihypertensive drug telmisartan inhibits cell proliferation of gastrointestinal stromal tumor cells in vitro

Authors:
- Hideki Kobara
- Shintaro Fujihara
- Hisakazu Iwama
- Takanori Matsui
- Ayako Fujimori
- Taiga Chiyo
- Shi Tingting
- Nobuya Kobayashi
- Noriko Nishiyama
- Tatsuo Yachida
- Tomoko Tadokoro
- Kyoko Oura
- Joji Tani
- Koji Fujita
- Takako Nomura
- Hirohito Yoneyama
- Asahiro Morishita
- Keiichi Okano
- Yasuyuki Suzuki
- Hirohito Mori
- Tsutomu Masaki
View Affiliations

Affiliations: Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Miki, Kita, Kagawa 761‑0793, Japan, Life Science Research Center, Kagawa University, Miki, Kita, Kagawa 761‑0793, Japan, Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Miki, Kita, Kagawa 761‑0793, Japan
Published online on: May 14, 2020 https://doi.org/10.3892/mmr.2020.11144
Pages: 1063-1071

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract. The angiotensin II type 1 receptor blockers, telmisartan and candesartan, are widely used antihypertensive drugs that inhibits cancer cell proliferation; however, its underlying mechanisms in mesenchymal tumors, including GIST, remains unknown. The present study aimed to investigate the effect of telmisartan on GIST‑T1 cells and its underlying mechanism. Telmisartan and candesartan inhibited the proliferation of these cells by blocking the G0 to G1 cell cycle transition, which was accompanied by a decrease in cell cycle‑related proteins such as cyclin D1. Furthermore, telmisartan exposure significantly altered microRNA expression in vitro. In conclusion, telmisartan suppressed human GIST cell proliferation by inducing cell cycle arrest in vitro.

View Figures

View References

1	Rubin BP, Heinrich MC and Corless CL: Gastrointestinal stromal tumor. Lancet. 369:1731–1741. 2007. View Article : Google Scholar : PubMed/NCBI
2	Giuliano K, Ejaz A, Reames BN, Choi W, Sham J, Gage M, Johnston FM and Ahuja N: Comparing the long-term outcomes among patients with stomach and small intestine gastrointestinal stromal tumors: An analysis of the National Cancer Database. J Surg Oncol. 118:486–492. 2018.PubMed/NCBI
3	Corless CL, Fletcher JA and Heinrich MC: Biology of gastrointestinal stromal tumors. J Clin Oncol. 22:3813–3825. 2004. View Article : Google Scholar : PubMed/NCBI
4	Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, et al: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol. 33:459–465. 2002. View Article : Google Scholar : PubMed/NCBI
5	Miettinen M and Lasota J: Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin Diagn Pathol. 23:70–83. 2006. View Article : Google Scholar : PubMed/NCBI
6	Yamamoto H and Oda Y: Gastrointestinal stromal tumor: Recent advances in pathology and genetics. Pathol Int. 65:9–18. 2015. View Article : Google Scholar : PubMed/NCBI
7	Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA and Kurtz TW: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-modulating activity. Hypertension. 43:993–1002. 2004. View Article : Google Scholar : PubMed/NCBI
8	Kinoshita J, Fushida S, Harada S, Yagi Y, Fujita H, Kinami S, Ninomiya I, Fujimura T, Kayahara M, Yashiro M, et al: Local angiotensin II-generation in human gastric cancer: Correlation with tumor progression through the activation of ERK1/2, NF-κB and survivin. Int J Oncol. 34:1573–1582. 2009. View Article : Google Scholar : PubMed/NCBI
9	Okamoto K, Tajima H, Ohta T, Nakanuma S, Hayashi H, Nakagawara H, Onishi I, Takamura H, Ninomiya I, Kitagawa H, et al: Angiotensin II induces tumor progression and fibrosis in intrahepatic cholangiocarcinoma through an interaction with hepatic stellate cells. Int J Oncol. 37:1251–1259. 2010. View Article : Google Scholar : PubMed/NCBI
10	Du N, Feng J, Hu LJ, Sun X, Sun HB, Zhao Y, Yang YP and Ren H: Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling. Oncology Rep. 27:18932012.
11	Chen X, Meng Q, Zhao Y, Liu M, Li D, Yang Y, Sun L, Sui G, Cai L and Dong X: Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer. Cancer Lett. 328:318–324. 2013. View Article : Google Scholar : PubMed/NCBI
12	Koyama N, Nishida Y, Ishii T, Yoshida T, Furukawa Y and Narahara H: Telmisartan induces growth inhibition, DNA double-strand breaks and apoptosis in human endometrial cancer cells. PLoS One. 9:e930502014. View Article : Google Scholar : PubMed/NCBI
13	Okazaki M, Fushida S, Harada S, Tsukada T, Kinoshita J, Oyama K, Tajima H, Ninomiya I, Fujimura T and Ohta T: The angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer. Cancer Lett. 355:46–53. 2014. View Article : Google Scholar : PubMed/NCBI
14	Bhaskaran K, Douglas I, Evans S, van Staa T and Smeeth L: Angiotensin receptor blockers and risk of cancer: Cohort study among people receiving antihypertensive drugs in UK general practice research database. BMJ. 344:e26972012. View Article : Google Scholar : PubMed/NCBI
15	Makar GA, Holmes JH and Yang YX: Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk. J Natl Cancer Inst. 106:djt3742014. View Article : Google Scholar : PubMed/NCBI
16	Funao K, Matsuyama M, Kawahito Y, Sano H, Chargui J, Touraine JL, Nakatani T and Yoshimura R: Telmisartan is a potent target for prevention and treatment in human prostate cancer. Oncol Rep. 20:295–300. 2008.PubMed/NCBI
17	Funao K, Matsuyama M, Kawahito Y, Sano H, Chargui J, Touraine JL, Nakatani T and Yoshimura R: Telmisartan as a peroxisome proliferator-activated receptor-gamma ligand is a new target in the treatment of human renal cell carcinoma. Mol Med Rep. 2:193–198. 2009.PubMed/NCBI
18	Lee L, Mafura B, Lauscher J, Seeliger H, Kreis M and Gröne J: Antiproliferative and apoptotic effects of telmisartan in human colon cancer cells. Oncol Lett. 8:2681–2866. 2014. View Article : Google Scholar : PubMed/NCBI
19	Rehman G, Shehzad A, Khan AL and Hamayun M: Role of AMP-activated protein kinase in cancer therapy. Arch Pharm (Weinheim). 347:457–468. 2014. View Article : Google Scholar : PubMed/NCBI
20	Dann SG and Thomas G: The amino acid sensitive TOR pathway from yeast to mammals. FEBS Lett. 580:2821–2829. 2006. View Article : Google Scholar : PubMed/NCBI
21	Fingar DC and Blenis J: Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 23:3151–3171. 2004. View Article : Google Scholar : PubMed/NCBI
22	Fujihara S, Asahiro M, Ogawa K, Tadokoro T, Chiyo T, Kato K, Kobara H, Mori H, Iwama H and Masaki T: The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo. Oncotarget. 8:8536–8549. 2017. View Article : Google Scholar : PubMed/NCBI
23	Oura K, Tadokoro T, Fujihara S, Morishita A, Chiyo T, Samukawa E, Yamana Y, Fujita K, Sakamoto T, Nomura T, et al: Telmisartan inhibits hepatocellular carcinoma cell proliferation in vitro by inducing cell cycle arrest. Oncol Rep. 38:2825–2835. 2017. View Article : Google Scholar : PubMed/NCBI
24	Liang LH and He XH: Macro-management of microRNAs in cell cycle progression of tumor cells and its implications in anti-cancer therapy. Acta Pharmacol Sin. 32:1311–1320. 2011. View Article : Google Scholar : PubMed/NCBI
25	Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:680–685. 1970. View Article : Google Scholar : PubMed/NCBI
26	Towbin H, Staehelin T and Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA. 76:4350–4354. 1979. View Article : Google Scholar : PubMed/NCBI
27	Benjamini Y and Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Stat Soc. 57:289–300. 1995.
28	de Araújo Júnior RF, Leitão Oliveira AL, de Melo Silveira RF, de Oliveira Rocha HA, de França Cavalcanti P and de Araújo AA: Telmisartan induces apoptosis and regulates Bcl-2 in human renal cancer cells. Exp Biol Med (Maywood). 240:34–44. 2015. View Article : Google Scholar : PubMed/NCBI
29	Sipahi I, Debanne SM, Rowland DY, Simon DI and Fang JC: Angiotensin-receptor blockade and risk of cancer: Meta-analysis of randomised controlled trials. Lancet Oncol. 11:627–636. 2010. View Article : Google Scholar : PubMed/NCBI
30	Shen J, Huang YM, Wang M, Hong XZ, Song XN, Zou X, Pan YH, Ling W, Zhu MH, Zhang XX, et al: Renin-angiotensin system blockade for the risk of cancer and death. J Renin Angiotensin Aldosterone Syst. 17(pii): 14703203166566792016.PubMed/NCBI
31	Masaki T, Shiratori Y, Rengifo W, Igarashi K, Yamagata M, Kurokohchi K, Uchida N, Miyauchi Y, Yoshiji H, Watanabe S, et al: Cyclins and cyclin-dependent kinases: Comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology. 37:534–543. 2003. View Article : Google Scholar : PubMed/NCBI
32	Kato K, Gong J, Iwama H, Kitanaka A, Tani J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, et al: The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther. 11:549–560. 2012. View Article : Google Scholar : PubMed/NCBI
33	Itami A, Shimada Y, Watanabe G and Imamura M: Prognostic value of p27^Kip1 and cyclin D1 expression in esophageal cancer. Oncology. 57:311–317. 1999. View Article : Google Scholar : PubMed/NCBI
34	Fukuchi M, Fukai Y, Kimura H, Sohda M, Miyazaki T, Nakajima M, Masuda N, Tsukada K, Kato H and Kuwano H: Prolyl isomerase Pin1 expression predicts prognosis in patients with esophageal squamous cell carcinoma and correlates with cyclinD1 expression. Int J Oncol. 29:329–334. 2006.PubMed/NCBI
35	Samples J, Willis M and Klauber-DeMore N: Targeting angiogenesis and the tumor microenvironment. Surg Oncol Clin N Am. 22:629–639. 2013. View Article : Google Scholar : PubMed/NCBI
36	Masaki T: MicroRNA and hepatocellular carcinoma. Hepatol Res. 39:751–752. 2009. View Article : Google Scholar : PubMed/NCBI
37	Morishita A and Masaki T: miRNA in hepatocellular carcinoma. Hepatology Res. 45:128–141. 2015. View Article : Google Scholar
38	Zhou Y, Wang M, Wu J, Jie Z, Chang S and Shuang T: The clinicopathological significance of miR-1307 in chemotherapy resistant epithelial ovarian cancer. J Ovarian Res. 8:232015. View Article : Google Scholar : PubMed/NCBI
39	Qiu X and Dou Y: miR-1307 promotes the proliferation of prostate cancer by targeting FOXO3A. Biomed Pharmacother. 88:430–435. 2017. View Article : Google Scholar : PubMed/NCBI